Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference
January 21 2022 - 7:30AM
Business Wire
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical
company focused on the development and commercialization of
treatments for hematologic malignancies, today announced that John
A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer,
will participate in a fireside chat at the B. Riley Securities
Virtual Oncology Investor Conference on Friday, January 28, 2022 at
11:00 a.m. ET.
A live webcast of the presentation will be available through the
Investor Relations section of Geron’s website under Events.
Following the presentation, the webcast will be archived and
available for replay for a period of 30 days.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused
on the development and potential commercialization of a
first-in-class telomerase inhibitor, imetelstat, in hematologic
malignancies. The Company currently is conducting two Phase 3
clinical trials: IMerge in lower risk myelodysplastic syndromes and
IMpactMF in refractory myelofibrosis. For more information about
Geron, visit www.geron.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220121005027/en/
Olivia Bloom Chief Financial Officer investor@geron.com
media@geron.com
Geron (NASDAQ:GERN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Sep 2023 to Sep 2024